Meridian Bioscience, Inc. (VIVO) Tops Q2 EPS by 2c; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $3.87 -4.91%
Financial Fact:
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED: -84.82M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Financial Fact:
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED: -84.82M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $47.4 million versus the consensus estimate of $44.82 million.
Meridian Bioscience, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Meridian Bioscience, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
- S&P Global completes sale of energy software portfolio to SLB
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
